Research & Commercialization
Though EBI comprises less than one percent of the Ohio University faculty, commercialization of technologies from EBI generated more than $200 million as of the end of 2011, more than 95 percent of the university’s royalty income. Ohio University ranks fourth in the nation in the Forbes survey of return on investment of research dollars.
Research at the institute continues a tradition of basic research combined with a disciplined, practical focus on commercialization in order to apply discoveries to the benefit of human health. Our research in molecular and cellular biology, genetics, proteomics, and hormonal regulation addresses unmet therapeutic needs in the areas of:
• Diabetes and obesity,
• Growth disorders,
• Aging, and
• Infectious diseases
These research themes are being pursued for the development of biomedical diagnostics and therapeutics both individually at EBI and in collaboration with other academic and corporate partners. Over the past three decades, this interdisciplinary and entrepreneurial approach has produced:
• 32 U.S. patents
• 14 U.S. patent applications pending
• 15 active invention disclosures
This science continues our best tradition and mission of enhancing not only human health globally but also the economic health of the southeastern Ohio region.